News • Women's health

Breast cancer treatment has evolved. Here’s where we are.

There is no “one size fits all approach” when it comes to treating breast cancer. The disease is made up of several subtypes, and ideally each type should be treated with therapies that target the unique underlying biological problems.

Photo
Associate professor of medicine, division of hematology and oncology at the David Geffen School of Medicine at UCLA and medical director of UCLA’s Jonsson Comprehensive Cancer Center Clinical Research Unit.

Fortunately, for the past 25 years, long-term survival and cure rates have significantly improved for women with breast cancer. This is due in large part to the development of drug therapies that target aggressive subtypes of breast cancer such as HER2-positive and ER positive breast cancers. Some of these life-prolonging and life-saving treatments, including Herceptin and IBRANCE, were developed at UCLA. Targeted therapies are now available for approximately 85 percent of women diagnosed with breast cancer.

Dr. Sara Hurvitz, associate professor of medicine, division of hematology and oncology at the David Geffen School of Medicine at UCLA and medical director of UCLA’s Jonsson Comprehensive Cancer Center Clinical Research Unit, says that despite these successes there is still work to do. One particularly aggressive subtype called triple negative breast cancer now comprises between 10 to 20 percent of all diagnosed breast cancers, and is challenging to treat.  Recent research focuses on identifying its biological underpinnings so that scientists can develop more effective and less toxic treatments.

For Breast Cancer Awareness Month, Hurvitz can discuss how breast cancer research has evolved and what types of targeted therapies are available to women with the disease.


Source: University of California, Los Angeles (UCLA), Health Sciences

09.10.2017

Read all latest stories

Related articles

Photo

Sponsored • Women's health

Improving Workflow and Patient Care Through Innovation

Groundbreaking technologies have improved our ability to accurately diagnose breast cancer and reduce callbacks, focusing on compassionate care for patients as they move along their breast health…

Photo

News • Women's health

Breast and ovarian cancer risk assessment from cervical samples

Scientists have discovered a means of identifying the risk of breast and ovarian cancer by measuring epigenetic changes in cervical samples from over a thousand women.

Photo

Sponsored • Breast imaging congress

EUSOBI 2021: A turning point in women’s health

The breast imaging field plays a critical role in women’s health and wellbeing around the globe. Bringing together experts, leaders and innovators from across the breast imaging landscape, the 2021…

Related products

AB-CT – Advanced Breast-CT – nu:view

Mammo CT

AB-CT – Advanced Breast-CT – nu:view

AB-CT – Advanced Breast-CT GmbH
Fujifilm – Amulet Bellus II

Mammo Workstations

Fujifilm – Amulet Bellus II

FUJIFILM Europe GmbH
Fujifilm – AMULET Innovality

Tomosynthesis

Fujifilm – AMULET Innovality

FUJIFILM Europe GmbH
Fujifilm – AMULET Innovality Harmony

Tomosynthesis

Fujifilm – AMULET Innovality Harmony

FUJIFILM Europe GmbH
Hologic – 3DQuorum SmartSlices

Artificial Intelligence

Hologic – 3DQuorum SmartSlices

Hologic, Inc.
Subscribe to Newsletter